Evidence map›Paper›PMID 29861799›Full record

ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2018

Sequential Measurements of Pentraxin 3 Serum Levels in Patients with Ventilator-Associated Pneumonia: A Nested Case-Control Study.

Huseyin Bilgin, Murat Haliloglu, Ali Yaman, Pinar Ay, Beliz Bilgili, Mustafa Kemal Arslantas, Filiz Ture Ozdemir, Goncagul Haklar, Ismail Cinel, Lutfiye Mulazimoglu

Abstract read
In one paragraph

Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huseyin BilginInfectious Diseases and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey.ORCID 0000-0002-5048-9970
Murat HalilogluDepartment of Anesthesiology and Intensive Care, Marmara University School of Medicine, Istanbul, Turkey.
Ali YamanDepartment of Biochemistry, Marmara University School of Medicine, Istanbul, Turkey.
Pinar AyDepartment of Public Health, Marmara University School of Medicine, Istanbul, Turkey.
Beliz BilgiliDepartment of Anesthesiology and Intensive Care, Marmara University School of Medicine, Istanbul, Turkey.
Mustafa Kemal ArslantasDepartment of Anesthesiology and Intensive Care, Marmara University School of Medicine, Istanbul, Turkey.ORCID 0000-0003-2838-9890
Filiz Ture OzdemirDepartment of Immunology, Marmara University School of Medicine, Istanbul, Turkey.
Goncagul HaklarDepartment of Biochemistry, Marmara University School of Medicine, Istanbul, Turkey.
Ismail CinelDepartment of Anesthesiology and Intensive Care, Marmara University School of Medicine, Istanbul, Turkey.
Lutfiye MulazimogluInfectious Diseases and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe main purpose of this study was to investigate the dynamics of pentraxin 3 (PTX3) compared with procalcitonin (PCT) and C-reactive protein (CRP) in patients with suspicion of ventilator-associated pneumonia (VAP). MATERIALS AND

methodsWe designed a nested case-control study. This study was performed in the Surgical Intensive Care Unit of a tertiary care academic university and teaching hospital. Ninety-one adults who were mechanically ventilated for >48 hours were enrolled in the study. VAP diagnosis was established among 28 patients following the 2005 ATS/IDSA guidelines.

resultsThe median PTX3 plasma level was 2.66 ng/mL in VAP adults compared to 0.25 ng/mL in non-VAP adults (

conclusionsWith the suspicion of VAP, a pentraxin 3 plasma breakpoint of 2.56 ng/mL could contribute to the decision of whether to start antibiotics.

Identifiers

PMID29861799
PMCPMC5971295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.